A pilot phase II study of neoadjuvant fulvestrant plus abemaciclib in women with advanced low-grade serous carcinoma.Lauren Cobb, Amir A. Jazaeri, Joseph Davis et al.|Journal of Clinical Oncology|2022Cited by 34
PPP2R1A mutations portend improved survival after cancer immunotherapyYibo Dai, Amir A. Jazaeri, Renganayaki Pandurengan et al.|Nature|2025Cited by 30
Phase II Trial of MEDI0457 and Durvalumab for Patients With Recurrent/Metastatic Human Papillomavirus-Associated CancersVan K. Morris, Michael Frumovitz, Amir A. Jazaeri et al.|The Oncologist|2023Cited by 29
Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum‐resistant ovarian cancerEmily Hinchcliff, Amir A. Jazaeri, Anne Knisely et al.|Cancer|2023Cited by 18
Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational OpportunitiesAnne Knisely, Amir A. Jazaeri, Yibo Dai et al.|Clinical Cancer Research|2025Cited by 10